Head to Head: Shire vs. Smith & Nephew


LONDON -- In this series, some of your favorite FTSE 100 shares go head to head in a three-round contest for superiority.

In Round 1, the firms fight on earnings; in Round 2, on dividends; and Round 3 is a battle of the balance sheets. The winner will be the company that has racked up most points at the end of the contest.

Stepping into the ring today are drugs company Shire (ISE: SHP.L) and medical devices firm Smith & Nephew (ISE: SN.L) .

Smith & Nephew has matched strides with the FTSE 100 over the past year, both having risen a bit more than 10%. Shire has moved in the opposite direction by a similar degree: down 12%.

Let's take our seats at ringside.

Round 1: Earnings


Smith & Nephew

Recent share price

1,770 pence

645 pence

Last year price-to-earnings ratio



Current year forecast P/E



Three-year earnings per share compound annual growth rate (%)



Current year forecast EPS growth (%)



Forecast operating margin (%)



Sources: Digital Look, Morningstar, company reports. Winners in bold.

Smith & Nephew scores points for its relatively low P/E, but Shire edges the first round thanks to very strong earnings growth and a superior operating margin.

Round 2: Dividends


Smith & Nephew

Last year dividend yield (%)



Current year forecast dividend yield (%)



Three-year dividend CAGR (%)



Current year forecast dividend growth (%)



Forecast dividend cover



Sources: Digital Look, Morningstar, company reports. Winners in bold.

In a reversal of round one, Smith & Nephew edges the second round, scoring on yield -- not exactly hard to better Shire's -- and taking a big-hitting point for forecast dividend growth.

You may be wondering why Smith & Nephew's forecast dividend growth is so far above the historical CAGR, especially when EPS growth is forecast to be minimal this year. The reason is that in the company's latest interim results the board announced a step-change increase in the level of dividend payout and a move to a progressive dividend policy. The interim dividend was lifted 50%. After this year's bumper rise, dividends will be broadly based on the group's "underlying growth in earnings, while taking into account capital requirements and cash flows."

Round 3: Balance sheet


Smith & Nephew

Price-to-book ratio



Net gearing (%)



Sources: Digital Look, Morningstar, company reports. Winners in bold.

Smith & Nephew finishes with a flourish, taking both points in the final round, giving it victory in two rounds to one. The overall points tally is Smith & Nephew seven, and Shire five.

Post-match assessment
Shire and Smith & Nephew are on higher P/Es and lower yields than the Footsie's pharma giants, GlaxoSmithKline and AstraZeneca.

Part of the reason for Shire and Smith & Nephews "growthier" ratings is that, though the companies aren't exactly small, it's easier for investors to envisage them doubling their market capitalization than it is to imagine super-heavyweights GlaxoSmithKline and AstraZeneca doubling theirs.

Smith & Nephew took all five points on the "value" measures I use in these head-to-head contests. In addition, the company's earnings -- and dividend-growth records and dividend cover -- are very decent; and it has sound business fundamentals in terms of a good operating margin and minimal gearing.

Supporters of Shire can point to its even stronger earnings growth record, even higher operating margin and dividend cover, and a perfectly respectable level of gearing, well below that of the average FTSE 100 company. Furthermore, Shire's forecast P/E isn't that much higher than Smith & Nephew's, while its forecast EPS growth certainly is.

For investors more interested in capital-growth potential than large, immediate cash-in-hand dividends, both companies in today's contest appear to be not unreasonably priced. Shire is an out-and-out blue-chip growth stock, while Smith & Nephew leans a little more towards growth and income with its new dividend policy.

Growth and income can be a powerful combination, as top equity-income fund manager Neil Woodford has shown. Woodford's funds have outperformed the market by more than 300% over the past 15 years.

If you'd like to learn about this City maestro's enormously successful investing strategy and the dividend-paying blue chips he currently favors, help yourself to the exclusive Motley Fool report, "8 Shares Held by Britain's Super Investor." The report is available for a limited time only, but you can download it for free right now: simply click here.

The article Head to Head: Shire vs. Smith & Nephew originally appeared on Fool.com.

G.A. Chester does not own shares in any of the companies mentioned in this article. The Motley Fool owns shares of Smith & Nephew. The Motley Fool has a disclosure policy.
We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. Try any of our Foolish newsletter services free for 30 days.

Copyright © 1995 - 2012 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.